The Minimum Clinically Important Difference in the Repeatable Battery for the Assessment of Neuropsychological Status

Phillips, Robert; Gao, Qi; Collinson, Simon L.; Ling, Audrey; Feng, Lei; Cheung, Yin Bun; Ng, Tze‐Pin

doi:10.1080/13854046.2015.1107137

Cited by 27 publications

(20 citation statements)

References 38 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Standard methods for detecting a minimum clinically important difference (MCID) in neurocognitive scores and other quality of life assessments typically suggest that changes exceeding 0.5 SD (i.e., 7.5 points for an IQ score) or 2 standard errors of measurement (SEM; typically around 3–6 points for index scores on the Wechsler scales) constitute a meaningful difference. 20 , 21 Applying the criterion of 0.5 SD for the MCID at the group level, observed declines from baseline to 2 years post-transplant could be considered clinically meaningful for the LS group in 4 neurocognitive domains: visual reasoning, processing speed, fine motor dexterity, and visual–motor integration. In contrast, no declines meeting this threshold were observed in the VLS group.…”

Section: Discussionmentioning

confidence: 99%

Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy

et al. 2020

View full text Add to dashboard Cite

ObjectiveTo quantify benchmark treatment outcomes that may be enabled by newborn screening surveillance for X-linked adrenoleukodystrophy (ALD), we report neurocognitive, neuropsychiatric, and MRI change for boys who underwent hematopoietic stem cell transplant (HSCT) at initial stages of demyelination, prior to neurocognitive signs of disease.MethodsRetrospective chart review identified 36 patients whose cerebral ALD was detected and treated early, with lesion severity less than 5 on the ALD-specific MRI scoring system. Median age at transplant was 7.3 years (range, 4.0–16.1). Progression of radiologic disease on MRI in the 2 years following HSCT was examined relative to the severity of the initial lesion for 33 patients, and longitudinal neurocognitive and neuropsychiatric outcomes were studied for 30 patients.ResultsPatients whose pretransplant lesion extended beyond the splenium of the corpus callosum and adjacent periventricular white matter (MRI severity score >2) demonstrated lower posttransplant neurocognitive scores, more neuropsychiatric symptoms, and more disease progression on MRI than patients with a less severe lesion. Changes from baseline neurocognitive functioning were greater at 2 years posttransplant as compared to 1 year. There was greater variance and risk of lesion progression as pretransplant MRI severity increased.ConclusionTo realize the full benefits of newborn screening, clinicians must detect very small demyelinating lesions during surveillance and intervene quickly. Novel interventions that reduce risks inherent in allogeneic transplantation are needed. Trial endpoints should include direct neurocognitive assessment and extend at least 2 years posttreatment to provide the greatest sensitivity to detect neurocognitive morbidity.

show abstract

Section: Discussionmentioning

confidence: 99%

Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Numerous research studies have been conducted regarding the ability of the measure to identify cognitive change in individuals with normal cognition (Andreotti & Hawkins, 2015; Cooley et al, 2015; Duff & Ramezani, 2015; Phillips et al, 2015; Thaler, Hill, Duff, Mold, & Scott, 2015), Mild Cognitive Impairment (MCI; Clark, Hobson, & O’Bryant, 2010; Duff, Hobson, Beglinger, & O’Bryant, 2010; Hobson, Hall, Humphreys-Clark, Schrimsher, & O’Bryant, 2010; Karantzoulis, Novitski, Gold, & Randolph, 2013; O’Mahar et al, 2012), and Alzheimer’s disease (AD; Burton, Enright, O’Connell, Lanting, & Morgan, 2015; Duff et al, 2008; Enright, O’Connell, MacKinnon, & Morgan, 2015; Heyanka, Scott, & Adams, 2015; McDermott & DeFilippis, 2010; Morgan, Linck, Scott, Adams, & Mold, 2010; Schmitt et al, 2010). Despite these efforts, however, there have been few studies examining the RBANS and its association with imaging biomarkers related to AD, such as decreased hippocampal volumes on magnetic resonance imaging (MRI; Choi et al, 2016; Jack et al, 2010), hypometabolism on fluoro-2-deoxyglucose (FDG) positron emission tomography (PET; Frings, Spehl, Hull, & Meyer, 2016; Jagust et al, 2010), and amyloid accumulations on amyloid PET (Beach, Thal, Zanette, Smith, & Buckley, 2016; L.…”

Section: Introductionmentioning

confidence: 99%

Relationship between ¹⁸F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults

Hammers

Atkinson

Dalley

et al. 2017

The Clinical Neuropsychologist

View full text Add to dashboard Cite

Objective The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has been used extensively for clinical care and in research for patients with Mild Cognitive Impairment and Alzheimer’s disease (AD), however relatively few studies have evaluated the relationship between RBANS performance and AD imaging biomarkers. The purpose of the current study was to evaluate the association between a relatively new amyloid positron emission tomography imaging biomarker and performance on the RBANS. Methods Twenty-seven non-demented community-dwelling adults over the age of 65 underwent 18F-Flutemetamol amyloid- positron emission tomography imaging, along with cognitive testing using the RBANS and select behavioral measures. Partial correlation coefficients were used to identify relationships between the imaging and behavioral markers. Results After controlling for age and education, amyloid deposition and RBANS Indexes of Immediate Memory, Delayed Memory, and Total Scale score were significantly correlated (p’s <.001, r’s =−0.73 to −0.77, d’s =2.13–2.39), with greater amyloid burden being associated with lower RBANS scores. The Delayed Memory Index was particularly highly associated with 18F-Flutemetamol binding (r2 =.59, p <.001, d =2.39). Neither 18F-Flutemetamol binding nor RBANS performance was significantly correlated with levels of depression, subjective cognitive difficulties, or premorbid intellect. Conclusions Because of the limited use of amyloid imaging in clinical settings due to high cost and lack of reimbursement, these findings suggest that in particular RBANS Delayed Memory Index may be a cost-efficient tool to identify early signs of AD pathology, and its use may enlighten clinical decision making regarding potential progression to dementia due to AD.

show abstract

“…for 1- s.e.m. of the MCID in cognition for mild cognitive impairment (Phillips et al ., 2015 ). In this study, anchor-based MCID in cognition ranged from 0.3 to 0.9.…”

Section: Discussionmentioning

confidence: 99%

“…The MCID also plays a crucial role in interpreting cognitive and functional scale scores in a clinical setting. Until now, interpreting results from such instruments have relied on the personal experience of clinicians treating populations with BD and thus lack objectivity (Phillips et al ., 2015 ). The MCID has been proposed as a more objective way to establish clinical relevance to changes in standardised instrument scores and can be used to assess the effectiveness of treatment.…”

Section: Introductionmentioning

confidence: 99%

Minimum clinically important differences for the Functioning Assessment Short Test and a battery of neuropsychological tests in bipolar disorders: results from the FACE-BD cohort

Roux

Brunet-Gouet

Ehrminger

et al. 2020

Epidemiol Psychiatr Sci

View full text Add to dashboard Cite

Aims Establishing the minimum clinically important difference (MCID) in functioning and cognition is essential to the interpretation of the research and clinical work conducted in bipolar disorders (BD). The present study aimed to estimate the MCID for the Functioning Assessment Short Test (FAST) and a battery of neuropsychological tests in BD. Methods Anchor-based and distributive methods were used to estimate the MCID for the FAST and cognition using data from a large, multicentre, observational cohort of individuals with BD. The FAST and cognition were linked with the Clinical Global Impressions Scale-Severity (CGI-S) and Global Assessment of Functioning (GAF) using an equipercentile method. The magnitude of the standard error measurement (s.e.m.) provided another estimate of the MCID. Results In total, 570 participants were followed for 2 years. Cross-sectional CGI-S and GAF scores were linked to a threshold ⩽7 on the FAST for functional remission. The MCID for the FAST equalled 8- or 9-points change from baseline using the CGI-S and GAF. One s.e.m. on the FAST corresponded to 7.6-points change from baseline. Cognitive variables insufficiently correlated with anchor variables (all ρ <0.3). One s.e.m. for cognitive variables corresponded to a range of 0.45 to 0.93-s.d. change from baseline. Conclusions These findings support the value of the estimated MCID for the FAST and cognition and may be a useful tool to evaluate cognitive and functional remediation effects and improve patient functional outcomes in BD. The CGI-S and GAF were inappropriate anchors for cognition. Further studies may use performance-based measures of functioning instead.

show abstract

The Minimum Clinically Important Difference in the Repeatable Battery for the Assessment of Neuropsychological Status

Cited by 27 publications

References 38 publications

Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy

Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy

Relationship between ¹⁸F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults

Minimum clinically important differences for the Functioning Assessment Short Test and a battery of neuropsychological tests in bipolar disorders: results from the FACE-BD cohort

Contact Info

Product

Resources

About

The Minimum Clinically Important Difference in the Repeatable Battery for the Assessment of Neuropsychological Status

Cited by 27 publications

References 38 publications

Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy

Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy

Relationship between 18F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults

Minimum clinically important differences for the Functioning Assessment Short Test and a battery of neuropsychological tests in bipolar disorders: results from the FACE-BD cohort

Contact Info

Product

Resources

About

Relationship between ¹⁸F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults